Latest Manufacturing News

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

1414 Degrees has completed key milestones on its SiBox technology, advanced SiBrick storage media towards mass production, and acquired an exclusive licence for innovative silicon nanoparticle tech, backed by a $1.214 million capital raise.

Zimi Limited reported a remarkable 367% increase in quarterly revenue alongside a successful $1.85 million capital raise and completion of its manufacturing relocation, setting the stage for accelerated growth in the smart home IoT sector.

Ionic Rare Earths advances its global rare earths strategy with significant UK government funding, increased heavy rare earth oxide production, and a $15.6 million capital raise backed by a strategic US investor.

Archer Materials has successfully demonstrated that its blood potassium Biochip can be fabricated on a silicon platform, matching clinical accuracy standards and accelerating its path to commercialisation.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

Latrobe Magnesium successfully commissioned its Demonstration Plant producing magnesium oxide and secured $10 million in funding, while receiving a $200 million financing interest from the U.S. Export Import Bank for its next-stage commercial plant.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Ansell Limited delivered a robust FY25 performance driven by organic growth, successful Kimberly-Clark PPE integration, and productivity gains, while advancing sustainability goals and managing trade headwinds.

MyEco Group reported a modest 2% sales increase in Q1 FY26, driven by strong council channel growth that offsets U.S. tariff-related setbacks. Operational restructuring and regulatory tailwinds underpin its medium-term outlook.